 |
|
|
 |
|
Rationale:
- The psychotherapy of PTSD is somewhat specialized in that certain techniques (not routine talk therapy) are most effective;
substantial clinical improvement is more likely when patients receive one of these treatments.
- Medications may reduce PTSD symptoms, but they are not recommended alone.
|
|
Evidence:
- Several types of psychotherapy are effective for PTSD, including cognitive and exposure therapies and anxiety management techniques.
Other techniques are more controversial (1; 18; 19).
- In a recent trial of cognitive and exposure therapies, 80% of patients who completed treatment recovered to the point that
they no longer met criteria for the diagnosis of PTSD (20). Another trial comparing cognitive-behavioral therapy and problem-centered therapy found that both were more effective than
wait list, but cognitive-behavioral therapy was not superior to problem-centered therapy (21).
- Although some had expressed concern that exposure therapy might exacerbate symptoms, despite positive outcomes in many studies,
a recent examination of dropout rates across 25 controlled studies found no difference in dropout rates between exposure and
cognitive therapies (22).
- In a randomized trial of 21 patients with PTSD, virtual reality exposure provided significantly greater improvement in PTSD
syndromes than in patients on a waitlist control group. Moreover, most of the patients had been unable to tolerate typical
imaginal exposure (23).
|
|
Comments:
- Data on the effectiveness of a recently developed psychotherapy technique known as eye movement desensitization and reprocessing
are mixed (18). This technique has many adherents, but there is no consensus among PTSD experts on its usefulness. No data support psychodynamic
psychotherapy, the most common general form of psychotherapy, for PTSD. Hypnosis is not recommended.
|
| FAQs |
|
|
|
Jeffrey P. Staab, MD, MS, is a consultant for Eli Lilly, Forest Laboratories, received honorarium from Abbott Laboratories, received grants from GlaxoSmithKline,
Pfizer. Michael Roy, MD, editorial consultant, received honorarium from PFizer.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|